Insider trading

Period: 120 months Stock: MDGL Plan: Discretionary × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

54 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

54 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

54 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

54 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
54 decisions over 120 months Remove this filter
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
54 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

54 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
17 Aug 2026
Kelley Shannon T General Counsel
Sold at will
$341.94K 664 at 514.97
5.5%
Not planned
20 Jul 2026
Sibold William John President and CEO
Sold at will 10×
$1.37M 2,500 at 547.30
1.2%
Not planned
18 May 2026
Soergel David Chief Medical Officer
Sold at will
$435.42K 844 at 515.90
7.1%
Not planned
6 Mar 2026
Sibold William John President and CEO
Sold at will
$718.32K 1,663 at 431.94
1.0%
Not planned
6 Mar 2026
Taub Rebecca Director
Sold at will
$212.08K 491 at 431.94
0.1%
Not planned
6 Mar 2026
Huntsman Carole Chief Commercial Officer
Sold at will
$180.98K 419 at 431.94
3.2%
Not planned
6 Mar 2026
Kelley Shannon T General Counsel
Sold at will
$155.50K 360 at 431.94
2.9%
Not planned
2 Mar 2026
Dier Mardi EVP and CFO
Sold at will
$505.39K 1,183 at 427.21
11.3%
Not planned
26 Jan 2026
Sibold William John President and CEO
Sold at will
$776.55K 1,577 at 492.42
1.1%
Not planned
26 Jan 2026
Taub Rebecca Director
Sold at will
$318.60K 647 at 492.42
0.1%
Not planned
20 Jan 2026
Taub Rebecca Director
Sold at will
$1.10M 2,238 at 490.77
0.5%
Not planned
4 Dec 2025
Sibold William John President and CEO
Sold at will
$1.38M 2,400 at 575.34
1.6%
Not planned
5 Nov 2025
BATE KENNETH Director
Sold at will 11×
$8.03M 16,575 at 484.30
86.3%
Sold half or more
9 Sep 2025
Sibold William John President and CEO
Sold at will
$3.24M 7,279 at 445.63
6.6%
Not planned
20 Aug 2025
BAKER BROS. ADVISORS LP Director · indirect
Bought 22×
$23.07M 59,901 at 385.16
3.2%
18 Aug 2025
BAKER BROS. ADVISORS LP Director · indirect
Bought 32×
$38.85M 105,782 at 367.26
5.9%
Largest buy in 3 yrs
15 Aug 2025
BATE KENNETH Director
Sold at will 6×
$3.65M 10,000 at 365.20
79.2%
Sold half or more
13 Mar 2025
CRAVES FRED B Director
Sold at will 8×
$2.52M 7,742 at 325.25
2.2%
Not planned
12 Mar 2025
CRAVES FRED B Director
Sold at will 5×
$2.56M 7,728 at 331.84
2.2%
Not planned
5 Mar 2025
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will 9×
$4.82M 14,113 at 341.32
79.1%
Sold half or more
28 Feb 2025
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will 2×
$418.49K 1,227 at 341.07
24.8%
Not planned
27 Feb 2025
BATE KENNETH Director
Sold at will 9×
$7.13M 20,000 at 356.44
91.3%
Sold half or more
27 Feb 2025
Daly James M Director
Sold at will 3×
$5.38M 15,470 at 347.45
89.0%
Sold half or more
24 Jan 2025
Sibold William John President and CEO
Sold at will
$531.02K 1,584 at 335.24
2.8%
Not planned
24 Jan 2025
Taub Rebecca Pres., R&D, and CMO
Sold at will
$217.24K 648 at 335.24
0.1%
Not planned
24 Jan 2025
Huntsman Carole Chief Commercial Officer
Sold at will
$116.33K 347 at 335.24
3.2%
Not planned
24 Jan 2025
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will
$34.53K 103 at 335.24
2.0%
Not planned
17 Jan 2025
Taub Rebecca Pres., R&D, and CMO
Sold at will
$461.79K 1,689 at 273.41
0.4%
Not planned
17 Jan 2025
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will
$120.85K 442 at 273.41
8.0%
Not planned
17 Jan 2025
Kelley Shannon T General Counsel
Sold at will
$75.73K 277 at 273.41
3.5%
Not planned
3 Dec 2024
CRAVES FRED B Director · indirect
Sold at will 2×
$1.14M 3,600 at 315.31
24.7%
Not planned
25 Nov 2024
CRAVES FRED B Director · indirect
Sold at will 2×
$1.19M 3,400 at 350.30
18.9%
Not planned
21 Nov 2024
Huntsman Carole Chief Commercial Officer
Sold at will
$218.04K 688 at 316.92
6.0%
Not planned
9 Sep 2024
Sibold William John President and CEO
Sold at will
$1.55M 6,363 at 243.83
10.2%
Not planned
14 Jun 2024
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will
$532.00K 1,900 at 280.00
25.7%
Not planned
12 Jun 2024
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will
$570.00K 2,000 at 285.00
26.7%
Not planned
21 May 2024
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will
$239.67K 1,036 at 231.34
15.9%
Not planned
15 Dec 2023
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will 2×
$477.00K 2,000 at 238.50
26.1%
Not planned
14 Dec 2023
BAKER BROS. ADVISORS LP Director · indirect
Bought 8×
$4.71M 20,633 at 228.32
1.2%
14 Dec 2023
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will 2×
$465.00K 2,000 at 232.50
26.1%
Not planned
13 Dec 2023
BAKER BROS. ADVISORS LP Director · indirect
Bought 16×
$17.81M 81,159 at 219.39
4.8%
Largest buy in 3 yrs
13 Dec 2023
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will 2×
$563.50K 2,500 at 225.40
30.6%
Not planned
12 Dec 2023
BAKER BROS. ADVISORS LP Director · indirect
Bought 30×
$7.55M 34,578 at 218.31
2.1%
12 Dec 2023
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will 2×
$283.20K 1,300 at 217.85
18.7%
Not planned
5 Dec 2023
Lynch Brian Joseph SVP and General Counsel
Sold at will
$227.33K 1,000 at 227.33
6.2%
Not planned
4 Dec 2023
Lynch Brian Joseph SVP and General Counsel
Sold at will 2×
$393.96K 1,800 at 218.87
10.7%
Not planned
30 Nov 2023
Lynch Brian Joseph SVP and General Counsel
Sold at will 3×
$613.73K 3,000 at 204.58
16.7%
Not planned
29 Nov 2023
Lynch Brian Joseph SVP and General Counsel
Sold at will 2×
$796.75K 4,000 at 199.19
21.1%
Not planned
21 Nov 2023
BAKER BROS. ADVISORS LP Director · indirect
Bought 20×
$12.13M 64,350 at 188.47
4.0%
Largest buy in 3 yrs
20 Nov 2023
BAKER BROS. ADVISORS LP Director · indirect
Bought 12×
$3.85M 20,709 at 185.74
1.3%
Showing 1–50 of 54. Page 1 of 2 Older →